Mallinckrodt Looks To Exit Investor Suit Over Antitrust Deal

By Hayley Fowler (July 18, 2018, 3:58 PM EDT) -- Mallinckrodt PLC and its top executives said Tuesday that investors knew of the antitrust risk linked to its infant seizure drug Acthar and have relied on "bad math" in accusing it of lying about the drug's dependence on federal revenue, urging a D.C. federal judge to put an end to the investors' suit....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!